(Q36376395)

13 August 2017

1 reference

title

Economic implications of nonadherence to highly active antiretroviral treatment in HIV patients (English)

1 reference

13 August 2017

anti-retroviral agent

0 references

2

Jean-Paul Moatti

1 reference

13 August 2017

Karine Lamiraud

1

1 reference

PubMed ID

16433579

13 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

Expert Opinion on Pharmacotherapy

13 August 2017

1 reference

13 August 2017

7

1 reference

13 August 2017

2

1 reference

13 August 2017

135-143

1 reference

Adherence to HIV combination therapy

13 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Lopinavir-Ritonavir: a new protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Adherence as a particular issue with protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

High levels of adherence do not prevent accumulation of HIV drug resistance mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

The cost effectiveness of combination antiretroviral therapy for HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

A review of the literature on the economics of noncompliance. Room for methodological improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Cost-effectiveness of adherence-enhancing interventions: a quality assessment of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

The cost-effectiveness of different management strategies for patients on chronic warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Cost analysis of once-daily ISMN versus twice-daily ISMN or transdermal patch for nitrate prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Perimenopausal bone density screening--will it help prevent osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Treatment adherence and risk of death after a myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

The relationship of treatment adherence to the risk of death after myocardial infarction in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Cost-benefit analysis and mammographic screening: a travel cost approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

Adherence - sticking to the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.2.135

21 January 2018

Identifiers

DOI

10.1517/14656566.7.2.135

1 reference

13 August 2017

1 reference

PubMed ID

16433579